Durvalumab shows promise as perioperative addition for muscle-invasive urothelial carcinoma
September 5th 2023Adding perioperative durvalumab to standard care for patients with resectable muscle-invasive urothelial carcinoma demonstrated promising event-free and overall survival rates in a phase 2 trial.
UGN-102 improves on current standard in low-grade intermediate-risk NMIBC
August 8th 2023The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.
Financial toxicity is a growing concern in urologic oncology
June 23rd 2023"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Bladder-sparing treatments show noninferior OS vs radical cystectomy in BCG-unresponsive NMIBC
June 19th 2023“Our results suggest that bladder-sparing treatments may be a safe approach in selected patients. Survival outcomes were not inferior compared to early radical cystectomy," says Wei Shen Tan, MD.
Emulating target trials using observational evidence to inform clinical decision-making
June 2nd 2023"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.